Press releases

Cheplapharm Arzneimittel GmbH Announces Receipt of Required Consents

 

Cheplapharm Arzneimittel GmbH

Cheplapharm Arzneimittel GmbH Announces Receipt of Required Consents in Connection with the
Consent Solicitation…

Read more  /  pdf

Cheplapharm Arzneimittel GmbH Announces Consent Solicitation

 

Cheplapharm Arzneimittel GmbH

Cheplapharm Arzneimittel GmbH Announces Consent Solicitation Relating to its

3.500% Senior Secured Notes due 2027

Read more  /  pdf

CHEPLAPHARM acquires rights to Rivotril®

 

Greifswald, 01/11/2021 - CHEPLAPHARM expanded its portfolio by acquiring the commercial rights for Rivotril® from Roche.

 

 

"As a successful start…

Read more  /  pdf

CHEPLAPHARM completes it´s largest acquisition so far

 

Greifswald, 01/05/2021 - CHEPLAPHARM successfully closes acquisition of cardiovascular and metabolic portfolio from Takeda

 

Last week CHEPLAPHARM…

Read more  /  pdf

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets

 

Greifswald, 01/04/2021 - Cheplapharm acquires the global rights for the products Atacand® and Atacand® Plus

 

CHEPLAPHARM has held the rights for…

Read more  /  pdf

CHEPLAPHARM donates over €200,000 for Christmas

 

This year CHEPLAPHARM donates €200,000 for the association Deutsch-Afrikanische Zusammenarbeit e.V. and 4.000€ for the Christmas Campaign of the…

Read more  /  pdf

CHEPLAPHARM proves its vigour

 

Cheplapharm successfully closes the first project with LEO Pharma

 

This week CHEPLAPHARM successfully closed the project with LeoPharma, which…

Read more  /  pdf

CHEPLAPHARM closes another product portfolio acquisition

 

This week Cheplapharm closed another deal of a product bundle which contains six molecules and 12 related brands, focused on the treatment of…

Read more  /  pdf

CHEPLAPHARM succeeds again: 1 Billion Euros (equivalent) of Senior Secured Notes placed with institutional Investors

CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.

Read more  /  pdf

CHEPLAPHARM announces pricing of Senior Secured Notes

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of

€575 Million 4.375% Senior Secured Notes due 2028

$500 Million 5.500% Senior Secured Notes due…

Read more  /  pdf

CHEPLAPHARM wins again

Greifswald, 05/15/2020 – The family-owned pharmaceutical company CHEPLAPHARM Arzneimittel GmbH got honoured with the highly coveted 'Axia Best Managed…

Read more  /  pdf